All In MedTech

FDA Clearance Tracker · P150038

EXABLATE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jul 11, 2016 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Jul 11, 2016

Approved

Time to decision

264 days

Received Oct 21, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150038
Device name
EXABLATE
Applicant
Insightec
Applicant location
Tirat Carmel
Received
Oct 21, 2015
Decided
Jul 11, 2016
Decision
Approved
Supplements
42 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code POH

FDA's approval statement

As written in FDA's record.

Approval for the ExAblate Model 4000 Type 1.0 System (ExAblate Neuro). This device is indicated for use in the unilateral Thalamotomy treatment of idiopathic Essential Tremor patients with medication-refractory tremor. Patients must be at least age 22. The designated area in the brain responsible for the movement disorder symptoms (ventralis intermedius) must be identified and accessible for targeted thermal ablation by the ExAblate device.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code POH (MR-guided focused ultrasound system).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Insightec

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.